Abstract library

14 results for "Borbath".
#90 The prognostic value of FDG-PET scan in neuroendocrine tumors: a retrospective analysis of 46 patients treated in one center
Introduction: Neuroendocrine tumors (NETs) are rare and generally indolent. For diagnostic purposes, the sensitivity of FDG-PET scan is known to be low in this setting, though when positive, its prognostic value is not well-defined in NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
#126 Assessment of the proliferation marker Ki-67 by endoscopic ultrasound guided-Fine Needle Aspiration (EUS-FNA) in pancreatic endocrine tumors: A comparative analysis with histology of the surgical specimen
Introduction: Assessment of the proliferative index by Ki-67 immuno-labelling is an important prognostic parameter for the biologic behavior of digestive neuroendocrine tumors, usually established on the histological specimen obtained after surgery or macro-biopsy. However, small pancreatic endocrine tumors (PET) are more and more often recognized by CT/MRI and diagnosed by EUS. The value of Ki-67 labelling index (Ki-67-LI) on fine needle aspiration (FNA) is not well-established in this setting, although regularly assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)
Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Raymond
#903 Health-Related Quality-of-Life (HRQoL) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) Treated with Everolimus (EVE): Results from an Open-label, Phase IIIb, Multicenter, Expanded Access Program (EAP)
Introduction: NET is associated with a considerable HRQoL burden.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Marianne Pavel
Authors: Pavel M, Unger N, Borbath I, Ricci S, ...
Keywords: everolimus, QoL, NET
#956 Treatment Practices in European Centers with Interest in Neuroendocrine Carcinomas and High Grade (G3) Neuroendocrine Tumors
Introduction: Aggressive neuroendocrine neoplasms (NEN) encompass both poorly differentiated carcinomas (NEC) and high grade neuroendocrine tumors (G3-NET) with a Ki-67 index >20%; WHO 2010.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Ingrid Holst Olsen
#979 Characteristics and Treatments of Patients with G3 Gastroenteropancreatic Neuroendocrine Tumors (G3-NET) and Neuroendocrine Carcinoma (NEC): A European Multicenter Retrospective Study
Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Maximilian Heetfeld
#1224 A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial
Introduction: Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtypes 1-3 and 5. An earlier phase I study showed antitumor activity of everolimus+pasireotide LAR (EVE+PAS) in NET.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Matthew H Kulke
#1235 The Belgian DNET Registry: A Prospective, National, Web-Based Registry of Digestive Neuro-Endocrine Tumours (NET). Status After 2 Years of Inclusion.
Introduction: NET are rare neoplasms. The Belgian Group of Digestive Oncology created a web-based registry to have an overview on incidence, diagnosis and therapies performed in Belgian pts. The DNET registry was launched in 01/2012.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Dr. Ivan Borbath
Keywords: Registry, Belgium
#1351 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover
Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p<0.001). OS difference favored SU (HR=0.41; 95% CI 0.19–0.89; p=0.02). At 2 years after study closure, median OS was 33.0 mo for SU vs 26.7 mo for PBO (HR=0.71; 95% CI 0.47–1.09; p=0.115).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Eric Raymond
Keywords: sutent, OS